Coronary/Structural Heart

First Cancer, Now Heart Disease…Color Genomics

Share by Ken Dropiewski on

More in Coronary/Structural Heart:

Share this story

A New Heart Disease Test Flings Color Genomics Into A Battle About Genetics In Medicine

Color Genomics, a Burlingame, Calif.-based startup that has made a name for itself by selling tests for genes that dramatically raise the risk of cancer, is moving into a new area: heart disease. In doing so, it is stepping even more deeply into a raging debate over the medical and economic value of plumbing our DNA.
Today Color is releasing a genetic test for a condition called familial hypercholesterolemia, or FH, which causes sky-high cholesterol levels and a corresponding increase in the risk of heart attacks and strokes…

Ken has been in the cardiac, vascular, and interventional space for over 20 years. He is a Partner with McDermott + Bull Executive Search, recognized by Forbes as one of the industry's best with offices across North America and in Europe. Ken is hired by innovative cardiovascular device and biotech companies to help build their best teams possible at the executive level. Prior to search, Ken had an award winning commercial career at Boston Scientific and Johnson & Johnson to include such prestigious awards as President's Club, Ring Club, and Grand Awards. dropiewski@mbexec.com

Leave a Comment

Your email address will not be published. Required fields are marked *

*